Bcl2 (original) (raw)
Latest News for: bcl2
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor
Caledonian Record 03 Jun 2026
... novel BCL2 inhibitor mesutoclax in myelodysplastic ....
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax ...
Nasdaq Globe Newswire 03 Jun 2026
InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety ... .
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
Nasdaq Globe Newswire 22 May 2026
The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies ... .
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma (Form 8-K) (BeOne Medicines AG)
Public Technologies 15 May 2026
FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma. BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the class.
BEQALZI™ (Sonrotoclax) von BeOne Medicines von der US-amerikanischen FDA als erster und einziger BCL2-Inhibitor für ...
The Galveston Daily News 14 May 2026
SAN CARLOS, Kalifornien--(BUSINESS WIRE)--Mai 14, 2026-- ....
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for ...
Business Wire 14 May 2026
Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; ...
- 1
Article Search
tools
You can search using any combination of the items listed below.
Language:
Sort:
Indexed:
Search:
Duplicates: